ResearcherShanghai Medical College of Fudan UniversityNo recent work listed
Zhenyu Liao
Matched on ORCID iD 0000-0003-4691-1400; OpenAlex author ID A5018534803. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2021: 1 paper · 2022: 2 papers · 2023: 3 papers
Papers 6
- Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1002/ijc.34468↗
- Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2023.216411↗
- Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.16879↗
- SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
- Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
- Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Long‐Yun Ye · 6 shared papers, 2021–2023 · strength 0.86
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Xianjun Yu · 6 shared papers, 2021–2023 · strength 0.86
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Weiding Wu · 5 shared papers, 2022–2023 · strength 0.75
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Tianjiao Li · 5 shared papers, 2022–2023 · strength 0.75
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Kaizhou Jin · 5 shared papers, 2022–2023 · strength 0.75
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Saimeng Shi · 4 shared papers, 2022–2023 · strength 0.62
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Qinglin Fei · 4 shared papers, 2022–2023 · strength 0.62
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal… DOI 10.1111/febs.16879↗
- Xuan Lin · 4 shared papers, 2021–2023 · strength 0.53
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. DOI 10.1016/j.ebiom.2022.104016↗
- Paper SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. DOI 10.1016/j.canlet.2022.01.026↗
- Huiru Zhang · 3 shared papers, 2022–2023 · strength 0.46
- Paper Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. DOI 10.1002/ijc.34468↗
- Paper Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenoca… DOI 10.1016/j.canlet.2023.216411↗
- Paper SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. DOI 10.1016/j.canlet.2022.01.026↗
- Huaxiang Xu · 3 shared papers, 2021–2022 · strength 0.36
- Paper Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. DOI 10.1016/j.ebiom.2022.104016↗
- Paper SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. DOI 10.1016/j.canlet.2022.01.026↗
- Paper Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. DOI 10.3390/cancers13153678↗
- Liang Liu · 3 shared papers, 2021–2022 · strength 0.36
- Paper Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. DOI 10.1016/j.ebiom.2022.104016↗
- Paper SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. DOI 10.1016/j.canlet.2022.01.026↗
- Paper Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. DOI 10.3390/cancers13153678↗
- Zhiwen Xiao · 2 shared papers, 2022 · strength 0.26
- Heli Gao · 2 shared papers, 2021–2022 · strength 0.23
- Wuhu Zhang · 2 shared papers, 2021–2022 · strength 0.23
- Wenquan Wang · 2 shared papers, 2021–2022 · strength 0.23
- Wei Chen · 1 shared paper, 2023 · strength 0.16
- Hao Li · 1 shared paper, 2022 · strength 0.13
- Jia Dong · 1 shared paper, 2021 · strength 0.10
- Xu Wang · 1 shared paper, 2021 · strength 0.10
- Xuan Han · 1 shared paper, 2021 · strength 0.10
- Hao Li · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.